 |
| Combination of | |
|---|---|
| IGF-1 | Growth factor |
| IGFBP-3 | Binding protein |
| Clinical data | |
| Trade names | Iplex |
| AHFS/Drugs.com | Monograph |
| Routes of administration | Injection |
| ATC code | |
| Identifiers | |
| ChemSpider |
|
| UNII | |
  (what is this?) (verify) | |
Mecasermin rinfabate (INN, USAN) (brand name Iplex), also known as rhIGF-1/rhIGFBP-3, is a drug consisting of recombinant human insulin-like growth factor 1 (IGF-1) and recombinant human insulin-like growth factor binding protein-3 (IGFBP-3) which is used for the treatment of amyotrophic lateral sclerosis (Lou Gehrig's disease).[1][2]
It is similar in action to mecasermin, but with fewer side effects (such as hypoglycemia).[3]
- ^ Williams RM, McDonald A, O'Savage M, Dunger DB (March 2008). "Mecasermin rinfabate: rhIGF-I/rhIGFBP-3 complex: iPLEX". Expert Opin Drug Metab Toxicol. 4 (3): 311–24. doi:10.1517/17425255.4.3.311. PMID 18363546. S2CID 71237825.
- ^ Kemp SF (March 2007). "Mecasermin rinfabate". Drugs Today. 43 (3): 149–55. doi:10.1358/dot.2007.43.3.1079876. PMID 17380212.
- ^ Kemp SF, Thrailkill KM (April 2006). "Investigational agents for the treatment of growth hormone-insensitivity syndrome". Expert Opin Investig Drugs. 15 (4): 409–15. doi:10.1517/13543784.15.4.409. PMID 16548790. S2CID 29352034.